Plasma Translocator Protein Levels and Outcomes of Acute Ischemic Stroke: A Pilot Study

Table 2

Clinical worsening and other outcome measures at discharge in relation to translocator protein (TSPO) levels.

	Total	Lower TSPO	Higher TSPO		OR (95% CI)
		(≤0.46 ng/ml)	(>0.46 ng/ml)
Clinical worsening, n (%)	13 (34.2)	2 (10.5)	11 (57.9)	0.001	11.69 (2.08–65.6)
mRS, mean (SD)	4.39 (1.22)	4.00 (1.1)	4.79 (1.2)	0.02
mRS ≥ 4, n (%)	30 (78.95)	12 (63.2)	18 (94.7)	0.01	10.50 (1.14–96.57)
BI, mean (SD)	32.8 (35.1)	46.3 (36.1)	19.2 (28.9)	0.02
BI ≤ 30, n (%)	21 (55.2)	7 (36.8)	14 (73.7)	0.02	4.80 (1.20–19.13)
Death, n (%)	8 (20.05)	2 (10.5)	6 (31.5)	0.23	3.92 (0.67–22.7)

mRS, modified Rankin Scale; BI, Barthal Index; OR, odds ratio; CI, confidence interval; SD, standard deviation.